Cargando…
Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. A...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Saúde Pública da Universidade de São Paulo
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522717/ https://www.ncbi.nlm.nih.gov/pubmed/34706042 http://dx.doi.org/10.11606/s1518-8787.2021055003734 |
_version_ | 1784585149290119168 |
---|---|
author | da Silva, Roberta Barros da Silva, Thales Philipe Rodrigues Sato, Ana Paula Sayuri Lana, Francisco Carlos Felix Gusmão, Josianne Dias Souza, Janaina Fonseca Almeida Matozinhos, Fernanda Penido |
author_facet | da Silva, Roberta Barros da Silva, Thales Philipe Rodrigues Sato, Ana Paula Sayuri Lana, Francisco Carlos Felix Gusmão, Josianne Dias Souza, Janaina Fonseca Almeida Matozinhos, Fernanda Penido |
author_sort | da Silva, Roberta Barros |
collection | PubMed |
description | OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS: The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION: This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population. |
format | Online Article Text |
id | pubmed-8522717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Faculdade de Saúde Pública da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-85227172021-10-22 Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais da Silva, Roberta Barros da Silva, Thales Philipe Rodrigues Sato, Ana Paula Sayuri Lana, Francisco Carlos Felix Gusmão, Josianne Dias Souza, Janaina Fonseca Almeida Matozinhos, Fernanda Penido Rev Saude Publica Original Article OBJECTIVE: To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS: Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS: The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION: This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population. Faculdade de Saúde Pública da Universidade de São Paulo 2021-10-05 /pmc/articles/PMC8522717/ /pubmed/34706042 http://dx.doi.org/10.11606/s1518-8787.2021055003734 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article da Silva, Roberta Barros da Silva, Thales Philipe Rodrigues Sato, Ana Paula Sayuri Lana, Francisco Carlos Felix Gusmão, Josianne Dias Souza, Janaina Fonseca Almeida Matozinhos, Fernanda Penido Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title | Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_full | Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_fullStr | Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_full_unstemmed | Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_short | Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais |
title_sort | adverse events following immunization against sars-cov-2 (covid-19) in the state of minas gerais |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522717/ https://www.ncbi.nlm.nih.gov/pubmed/34706042 http://dx.doi.org/10.11606/s1518-8787.2021055003734 |
work_keys_str_mv | AT dasilvarobertabarros adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT dasilvathalesphiliperodrigues adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT satoanapaulasayuri adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT lanafranciscocarlosfelix adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT gusmaojosiannedias adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT souzajanainafonsecaalmeida adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais AT matozinhosfernandapenido adverseeventsfollowingimmunizationagainstsarscov2covid19inthestateofminasgerais |